Clinical Trials
114 trialsNCT06890338 2026-05-13
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT03393884 2026-05-04
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT06915025 2026-05-04
OVATION-3
Imunon
Phase 3 Recruiting
NCT04516447 2026-04-07
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT04498117 2026-04-01
FLORA-5
CanariaBio Inc.
Phase 3 Active not recruiting
NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT05737303 2025-02-11
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Recruiting
NCT02124421 2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2 Active not recruiting
NCT04493619 2024-11-04
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
Phase 1/2 Terminated
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT02312661 2024-05-06
OVMET
University Medical Center Groningen
Phase 1 Completed
NCT01402271 2023-12-11
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT02834975 2023-11-07
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Phase 2 Terminated
NCT01164995 2023-09-07
M10MKO
The Netherlands Cancer Institute
Phase 2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT03321188 2023-02-06
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Phase 2 Unknown
NCT00373217 2022-09-21
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
Phase 2 Terminated
NCT03794778 2022-07-18
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 4 Unknown
NCT02107937 2022-05-04
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT03607955 2021-09-29
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Washington University School of Medicine
Phase 1 Withdrawn
NCT02303912 2021-05-18
ProGem2
Imperial College Healthcare NHS Trust
Phase 1 Completed
NCT01146795 2021-02-09
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
Phase 2 Completed
NCT02822157 2021-01-29
CLIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Unknown
NCT03480750 2020-11-10
Trientine
National Cheng-Kung University Hospital
Phase 1/2 Completed
NCT01249443 2020-07-29
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
Phase 1 Terminated
NCT00030446 2020-04-08
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00028743 2020-04-02
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT02487849 2020-03-04
HIPEC
Krankenhaus Barmherzige Schwestern Linz
Phase 2 Withdrawn
NCT01663857 2019-09-11
A Study LY2228820 for Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT04063527 2019-08-30
Phase III Trial of Stage I Ovarian Cancer After Surgery
Japanese Gynecologic Oncology Group
Phase 3 Recruiting
NCT00993616 2019-07-23
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079430 2019-07-22
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00085358 2019-07-22
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
National Cancer Institute (NCI)
Phase 1 Completed
NCT01281514 2019-07-11
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT00003644 2019-06-04
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
GOG Foundation
Phase 3 Completed
NCT00003214 2019-05-15
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
Swiss Cancer Institute
Phase 3 Completed
NCT00652691 2019-04-08
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Mayo Clinic
Phase 1 Completed
NCT02050009 2019-02-20
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1 Withdrawn
NCT00002600 2019-02-06
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02046421 2018-09-11
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 1 Completed
NCT02107950 2018-08-15
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT00331422 2017-12-28
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00562185 2017-11-20
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT02437812 2017-02-28
Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
Gynecologic Oncology Associates
Phase 2 Unknown